3-­‐V Biosciences to Present Data at the 18th ECCO -­‐ 40th ESMO European Cancer Congress in Vienna Menlo Park, California, September 17, 2015. 3-­‐V Biosciences, Inc., a clinical-­‐stage biopharmaceutical company developing therapeutics in oncology, announced today that it will present data from its ongoing Phase 1 clinical study at the 18th ECCO -­‐ 40th ESMO European Cancer Congress to be held September 25-­‐29 in Vienna, Austria. The late-­‐breaking abstract titled “Evidence of activity of a new mechanism of action (MoA): A first-­‐in-­‐human study of the first-­‐in-­‐
class fatty acid synthase (FASN) inhibitor, TVB-­‐2640, as monotherapy or in combination” has been selected for an oral presentation as part of a session titled "Early Drug Development II" on September 27, 2015 at 5:00PM local time. The Principal Investigator presenting details about the trial is Dr. Hendrik-­‐Tobias Arkenau from the Sarah Cannon Research Institute – United Kingdom, which is a part of the cancer enterprise for Hospital Corporation of America. “We are encouraged to see the clinical momentum building in the ongoing study with TVB-­‐2640. The progress we have seen in the clinical development of this FASN inhibitor has demonstrated an encouraging safety and efficacy profile, and I look forward to presenting our research updates for this first-­‐in-­‐class agent,” commented Dr. Arkenau. Abstract information is as follows: Late-­‐breaking Abstract #27LBA: Evidence of activity of a new mechanism of action (MoA): A first-­‐in-­‐human study of the first-­‐in-­‐class fatty acid synthase (FASN) inhibitor, TVB-­‐2640, as monotherapy or in combination. Proffered Paper Session: Early Drug Development II Presentation date: 9/27/2015 Presentation time: 5:00pm local time Speaker: H.T. Arkenau (United Kingdom) About the European Society for Medical Oncology The European Society for Medical Oncology (ESMO) is the leading European professional organization committed to advancing the specialty of medical oncology and promoting an integrated approach to cancer treatment and care. ESMO’s mission is to advance cancer care and cure through fostering and disseminating good science that leads to better medicine and determines best practice. ESMO’s scientific journal, Annals of Oncology, ranks among the top clinical oncology journals worldwide. ESMO events are the meeting place in Europe for medical oncologists to update their knowledge, to network and to exchange ideas. To find out more about ESMO, please visit: www.esmo.org. About 3-­‐V Biosciences 3-­‐V Biosciences, Inc. is a clinical-­‐stage pharmaceutical company developing novel therapeutics in oncology based on expertise in lipid biology. The company’s lead oncology product candidate is a first-­‐in-­‐class inhibitor of fatty acid synthase (FASN) currently being evaluated in a Phase 1 clinical trial for the treatment of solid tumors. Lipids are integral to cellular metabolism, cellular signaling and cellular structure and the emerging understanding of lipid biology opens up promising new areas for drug development. Together with a group of world-­‐renowned experts in lipid biology, we have established expertise to translate this biology into patient benefit with a focus on oncology drug development. The company is located in Menlo Park, California. For additional information on 3-­‐V Biosciences, please visit www.3vbio.com. # # # Investor Relations Contact: Jamien Jones Blueprint Life Science Group Telephone: 415.375.3340 Ext. 5 jjones@bplifescience.com